Effect of Growth Hormone Therapy on Adult Height of Children with Turner Syndrome  by Hsu, Ping-Yi et al.
704 J Formos Med Assoc | 2008 • Vol 107 • No 9
ORIGINAL ARTICLE
Turner syndrome was first described by Henry
Turner in 1938 as a syndrome of infantilism, con-
genital webbed neck and cubitus valgus caused
by the complete or partial absence of X chromo-
some.1,2 Short stature is a common manifestation
in these children, which may impair their quality
of life.1,3–5
Initially, Turner et al reported that growth hor-
mone (GH) could not improve the adult height
of their patients,1 but several subsequent studies
have since demonstrated the effectiveness of 
GH therapy in Turner syndrome patients over
the past 20 years.6–19 There is considerable varia-
tion in the treatment protocols for GH therapy 
of Turner syndrome patients in the litera-
ture.6,7,9,11,14–19 One study has reported that the
combination of GH with fluoxymesterolone can
improve the adult height of children with Turner
syndrome in Taiwan.20 However, an effect of GH
alone on the adult height of these patients in
Taiwan is lacking. Therefore, the present study
was conducted to investigate the effect of GH
therapy alone on the adult height of Turner 
syndrome patients.
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Background/Purpose: Short stature is a common manifestation of Turner syndrome. The purpose of this
study was to evaluate the effect of growth hormone (GH) therapy alone on the adult height of children with
Turner syndrome.
Methods: From 1987 to 2006, 21 Turner syndrome patients who had been treated with GH for > 2 years
and had reached adult height were enrolled in the study. The dosage of GH was 0.33 mg/kg/week. Estrogen
replacement therapy was prescribed at the age of 15.6±0.9 years, if indicated. The patients had been followed-
up until they reached their adult height. During the same period, 28 Turner syndrome patients who were not
treated with growth-promoting agents were enrolled for comparison. Mann-Whitney U test and Wilcoxon
signed rank test were used for comparison.
Results: Twenty-one patients in the study group started GH therapy at the age of 11.5 ±1.8 years. The duration
of GH therapy was 4.0 ± 1.5 years. The growth rate before treatment was 3.8 ± 0.7 cm/year, which increased
to 7.1 ± 1.4, 5.4 ± 1.4 and 4.7 ± 0.9 cm/year during the first 3 years of GH therapy, respectively. Patients
who received GH reached an adult height of 150.0 ± 5.1 cm, which was significantly higher than the
144.7 ± 5.9 cm of the control group (p < 0.05). The adult height of the study group was 6.3 ± 3.3 cm taller
than their projected adult height upon enrolment. No major adverse events were detected during GH therapy.
Conclusion: GH alone is safe and effective for the promotion of growth in children with Turner syndrome
in Taiwan. [J Formos Med Assoc 2008;107(9):704–709]
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Methods
The medical records of Turner syndrome patients
who visited the National Taiwan University
Hospital between 1987 and 2006 were reviewed.
Diagnosis was made on the basis of their clinical
phenotype and confirmed by karyotype analysis of
peripheral blood leukocytes. Twenty-one patients
who received GH therapy for >2 years and reached
an adult height were enrolled. For comparison,
28 Turner syndrome patients who were never
treated with growth-promoting drugs were en-
rolled as controls.
Study group
Twenty-one patients who had not been treated with
growth-promoting agents were enrolled for GH
therapy. They did not have any clinical evidence of
severe cardiovascular diseases, renal diseases, sco-
liosis or other major systemic diseases. Chromo-
some analysis demonstrated a 45,X karyotype in
eight patients, mosaicism in 12 patients, and struc-
tural abnormalities of the X chromosome in one
patient. After baseline observation for > 6 months,
GH was prescribed at a dose of 0.33 mg/kg/week.
At the start of treatment, the chronological age
was 11.5 ± 1.8 years and bone age was 10.0 ± 1.9
years, according to Greulich and Pyle’s standards.21
Body height was −3.2 ± 0.8 standard deviations
(SD) below the mean height of normal Taiwanese
girls of the same age. The mean growth rate was
3.8 ± 0.7 cm/year. GH therapy was continued un-
til the patients grew < 4 cm/year, or when they
and their parents were satisfied with the height
achieved. The duration of GH treatment was
4.0 ± 1.5 years.
Only one patient had spontaneous puberty
and menstruation, and hormone replacement
therapy was prescribed for the other 20 patients.
The average age at the start of estrogen therapy
was 15.6 ± 0.9 years. Administration of conjugated
estrogens was initiated at 0.3 mg/day, which was
increased to 0.625 mg/day, and given cyclically
with the addition of progesterone after 1 year.
The patients have been regularly followed-up
at our pediatric endocrine clinic at least once every
3 months. During the period of GH therapy, body
height and weight, signs of puberty, complete
blood count, fasting blood glucose level, and
plasma HbA1c levels were checked once every 
3 months. Bone age, thyroid autoantibodies, and
thyroid function were checked once every 6
months.
Control group
Twenty-eight patients who had never been treated
with growth-promoting agents were enrolled as
the control group. Chromosome study showed 
a 45,X karyotype in seven patients, mosaicism in
16 patients, and structural abnormalities of the 
X chromosome in five patients. Twenty-three pa-
tients had not been treated with GH because
their parents refused treatment, and they were
followed-up until their adult height was reached.
The other five patients were too old to receive GH
therapy paid for by health insurance on their first
visit to our hospital. Estrogen replacement ther-
apy was indicated in 20 of the 28 patients. Their
age at the start of therapy was 16.4 ± 2.4 years.
The treatment protocol was the same as that of
the study group.
Auxological parameters
Patient height was obtained by direct measure-
ment on a wall-mounted Harpenden stadiometer,
while the growth rate was calculated using meas-
urements for 6–12 months. The target height (TH)
was calculated using the following equation: 
(mother’s height + father’s height − 13)/2 cm
Adult height was considered when the annual
growth rate was < 2 cm and the bone age was
> 15 years. The projected adult height (PAH) of
the patients was estimated according to the data
described by Lyon et al.3 In the control group,
there was a good correlation between height stan-
dard deviation scores (SDS) on the first visit of the
patient and those of their observed adult height
(r = 0.81). Therefore, Turner-specific reference data
described by Lyon et al were used to estimate PAH
in this study.
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Statistical analysis
Numerical data in this study were presented as
mean ± SD. Mann-Whitney U test and Wilcoxon
signed rank test were used for comparison of nu-
merical data and p < 0.05 was considered statisti-
cally significant. Correlations between adult height
SDS and variables were analyzed by Spearman’s
rank test.
Results
In the control group, there was no statistically sig-
nificant difference in the PAH or observed adult
height between those receiving estrogen therapy
and those with spontaneous puberty. Neither 
the study nor control group had a statistically
significant difference in PAH or observed adult
height between patients with mosaicism and
those with non-mosaicism. Therefore, these data
were grouped together.
As shown in the Table, there were no statisti-
cally significant differences in age, height, Turner
height SDS, PAH and TH between the group 
receiving GH therapy and the control group upon
enrolment.
There was a marked increase in growth rate,
from 3.8 ± 0.7 to 7.1 ± 1.4 cm/year, during the first
year of GH therapy (Figure 1). The change in
growth rate was not as dramatic in the following
years, but there were statistically significant in-
creases in growth rate during the first 3 years of
GH therapy, as compared with the baseline growth
rate.
There was no statistically significant difference
between PAH and the observed adult height in
the control group at the end of the study (Table).
Table. Auxological data of patients with Turner syndrome
GH Control p
Baseline data
Age (yr)* 11.5 ± 1.8 12.9 ± 4.0 0.154
Height (cm) 125.2 ± 7.8 129.7 ± 13.4 0.088
Height SDS −3.2 ± 0.8 −2.9 ± 1.1 0.129
Turner height SDS† 0.1 ± 0.7 0.4 ± 0.9 0.146
PAH (cm)† 143.8 ± 4.0 145.7 ± 5.6 0.157
TH (cm) 156.4 ± 3.0 155.5 ± 4.7 0.363
Age at estrogen therapy (yr) 15.6 ± 0.9 16.4 ± 2.4 0.223
Data at end of study
Last age (yr) 20.6 ± 3.1 20.6 ± 4.2 0.840
Adult height (cm) 150.1 ± 5.1 144.7 ± 5.9 0.004
Adult height SDS −1.7 ± 0.9 −2.7 ± 1.1 0.004
 Adult height − PAH (cm) 6.3 ± 3.3 −1.0 ± 3.7 < 0.001
 Adult height − TH (cm) −6.3 ± 4.5 −10.9 ± 6.7 0.019
*Baseline age was the age at the start of growth hormone therapy for the study group and the age at the first visit for the control
group; †estimated using the method of Lyon et al.3 SDS = standard deviation scores; PAH = projected adult height; TH = target 
height.
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Figure 1. Growth rate during growth hormone therapy in
Turner syndrome. Numbers in parentheses denote number
of patients. *p < 0.05.
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On the other hand, the adult height of the study
group, who were treated with GH for 4.0 ± 1.5
years, was significantly higher than the PAH and
adult height of the control group. The difference
between adult height and TH was −6.3 ± 4.5 cm
in the study group and −10.9 ± 6.7 cm in the con-
trol group, which was statistically significant.
Although the average adult height of Turner 
syndrome patients treated with GH was 150.0 ±
5.1 cm, which was −1.7 ± 0.9 SD below the mean
adult height of normal Taiwanese women, 57%
achieved an adult height above the third per-
centile for normal Taiwanese adult women.
The increment in height relative to PAH in pa-
tients with Turner syndrome is shown in Figure 2.
The height increment in patients treated with GH
was significantly greater than the change in height
of patients without GH therapy. However, two
patients in the study group had no obvious height
gain after 2 years of GH therapy.
When covariance was analyzed with adult
height as the end point, a significant positive
correlation was observed with TH (r = 0.467),
baseline height SDS (r = 0.689), baseline growth
rate (r = 0.525), and growth rate during the first
year of therapy (r = 0.440). However, no signifi-
cant correlation was demonstrated with age at
the start of GH therapy and duration of therapy.
GH therapy was well tolerated. There were no
episodes of leukemia, neoplasm, diabetes mellitus,
hypothyroidism, slipped capital femoral epiphysis,
or benign intracranial hypertension during the
study period.
Discussion
The mean observed adult height of the control
group (144.7 ± 5.9 cm) was similar to their PAH
(145.7±5.6 cm), estimated by the method of Lyon
et al upon study entry,3 which suggests that the
method is applicable for estimating the adult
height of Taiwanese patients with Turner syn-
drome. The observed adult height of the control
group was higher than that previously reported
for Turner syndrome in Taiwan.20,22 The fact that
only those with severe manifestations of Turner
syndrome tended to seek medical help in previous
times may partially explain such a discrepancy.
The growth rate was markedly increased during
the first year of GH therapy. Such an increment
was not as remarkable during the second year of
therapy, as previously reported.23 However, there
was still a statistically significant increase in growth
rate above baseline in the first 3 years of GH ther-
apy. Based on the differences between annual
growth rate after GH therapy and baseline growth
rate, it was estimated that up to 77% of the total
increase in adult height above PAH was obtained
during the first 3 years of GH therapy.
The observed adult height of the study group
was 150.1 ± 5.1 cm, which was 6.3 ± 3.3 cm taller
than their PAH, and 95% had an adult height
greater than their PAH. The adult height was also
better than that of the control group, which was
comparable to that reported in the literature.6–19
Although the adult height of the study group 
was shorter than their TH, 57% were taller than
the third percentile for normal adult height of
Taiwanese women.
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Figure 2. Height gain over projected adult height (PAH) for
patients treated with growth hormone (GH) compared with
controls. Data were plotted for individual patients with adult
height minus pretreatment PAH. The mean values for each
group are indicated by a dash.
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It has been reported that the adult height of
Taiwanese children with Turner syndrome can be
improved by treatment with a combination of GH
and fluoxymesterolone.20 The TH and observed
adult height in our study group were similar to
those reported by Shu,20 which implies that GH
therapy alone is as effective as combination ther-
apy in Taiwanese children with Turner syndrome.
On the other hand, GH therapy alone avoids the
androgenic side effects of fluoxymesterolone in
combination therapy.20 However, two of 21 pa-
tients (9.5%) treated with GH had their observed
adult height similar to their PAH. Such a phenom-
enon has also been noted previously,7,15,24,25 which
suggests that individual variations in response to
GH therapy do exist in Taiwanese patients with
Turner syndrome.
The adult height of children with Turner syn-
drome treated with GH was related to their TH,
baseline height SDS, baseline growth rate, and
growth rate during the first year of therapy as pre-
viously reported.10,19,20 Although there was no
notable correlation between the observed adult
height and age at onset or duration of GH ther-
apy, early initiation of GH therapy in patients
with Turner syndrome is advisable, so that puberty
can be induced at the appropriate age during
adolescence.8,11,17
The fact that no obvious major side effects were
observed in patients receiving GH therapy during
the study period confirms its safety.
Our study has all the limitations inherent in a
retrospective study. A large double-blind, placebo-
controlled, prospective study is required to con-
firm our findings. Our study showed that GH
therapy alone is safe and effective for improving
the adult height of patients with Turner syndrome
in Taiwan. 
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